
51 - 200 employees
Founded 2020
🏥 Healthcare
🧬 Biotechnology
💊 Pharmaceuticals
💰 $81M Series B - Evozyne on 2023-09
Healthcare • Biotechnology • Pharmaceuticals
Evozyne is an AI-native biotechnology company that designs de novo therapeutic proteins to treat immune‑mediated diseases. Its EvoGen generative AI engine designs protein sequences optimized for potency, stability, specificity, and low immunogenicity, and its EvoLab high-throughput experimental facility builds and tests thousands of candidates each design cycle to generate proprietary data. Evozyne advances engineered proteins—including IgG proteases, next‑generation cytokines, and respiratory disease candidates—toward clinical evaluation to address patients who do not respond to existing biologics or small molecules.
Selected: 🆕 Date Added.
🕒 May 22
Preclinical program leader advancing Evozyne’s AI-designed therapeutic proteins from candidate nomination through IND submission. Owning timelines, vendors, studies, and scalable operating processes across multiple assets.
🌽 Illinois – Remote
💵 $175k - $250k / year
💰 $81M Series B - Evozyne on 2023-09
⏰ Full Time
🟠 Senior
👔 Director
👻 Ghost score 43%